Flublok Trivalent Northern Hemisphere - INFLUENZA A VIRUS A/WEST VIRGINIA/30/2022 (H1N1) RECOMBINANT HEMAGGLUTININ ANTIGEN, INFLUENZA A VIRUS A/District of Columbia/27/2023 (H3N2) RECOMBINANT HEMAGGLUTININ ANTIGEN, and INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 RECOMBINANT HEMAGGLUTININ ANTIGEN 45 ug / .5mL; 45 ug / .5mL; 45 ug / .5mL Injection 0.5 mL
Reference details for licensed healthcare facility review and verification.
| NDC 11 | 49281-0725-10 |
|---|---|
| Product NDC | 49281-0725 |
| Generic Drug Name | INFLUENZA A VIRUS A/WEST VIRGINIA/30/2022 (H1N1) RECOMBINANT HEMAGGLUTININ ANTIGEN, INFLUENZA A VIRUS A/District of Columbia/27/2023 (H3N2) RECOMBINANT HEMAGGLUTININ ANTIGEN, and INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 RECOMBINANT HEMAGGLUTININ ANTIGEN |
| Brand Name | Flublok Trivalent Northern Hemisphere |
| Manufacturer | Sanofi Pasteur Inc. |
| Strength | 45 ug / .5mL; 45 ug / .5mL; 45 ug / .5mL |
| Dosage Form | Injection |
| Drug Type | Intramuscular |
| Package Quantity | 10 Syringe |
| Package Description | 10 SYRINGE in 1 CARTON (49281-725-10) / .5 mL in 1 SYRINGE (49281-725-88) |
| Active Ingredients | Influenza A Virus A/District Of Columbia/27/2023 (H3N2) Recombinant Hemagglutinin Antigen; Influenza A Virus A/West Virginia/30/2022 (H1N1) Recombinant Hemagglutinin Antigen; Influenza B Virus B/Austria/1359417/2021 Recombinant Hemagglutinin Antigen |
| Marketing Category | BLA |
Unless explicitly stated in writing, no direct affiliation, sponsorship, or endorsement by individual product manufacturers with Premium Rx National, LLC should be implied. All brand names, trade names, and trademarks are the property of their respective owners and are presented solely for accurate product identification and informational reference.
NDC snapshot
INFLUENZA A VIRUS A/WEST VIRGINIA/30/2022 (H1N1) RECOMBINANT HEMAGGLUTININ ANTIGEN, INFLUENZA A VIRUS A/District of Columbia/27/2023 (H3N2) RECOMBINANT HEMAGGLUTININ ANTIGEN, and INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 RECOMBINANT HEMAGGLUTININ ANTIGEN 45 ug / .5mL; 45 ug / .5mL; 45 ug / .5mL Injection is tracked under NDC 49281-0725-10 and rolls up into product family 49281-0725. Use this page to review package-level identifiers before comparing related family pages or starting a quote review.
- Package configuration: 10 Syringe.
- Manufacturer: Sanofi Pasteur Inc..
- Dosage form: Injection.
- Family size: 1 indexed presentation.
Click a tag to refine the catalog view around this product reference.
Official references
Use official labeling and directory references to confirm presentation details while your team reviews the PRN catalog entry and related sourcing paths.
Flublok Trivalent Northern Hemisphere - INFLUENZA A VIRUS A/WEST VIRGINIA/30/2022 (H1N1) RECOMBINANT HEMAGGLUTININ ANTIGEN, INFLUENZA A VIRUS A/District of Columbia/27/2023 (H3N2) RECOMBINANT HEMAGGLUTININ ANTIGEN, and INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 RECOMBINANT HEMAGGLUTININ ANTIGEN 45 ug / .5mL; 45 ug / .5mL; 45 ug / .5mL Injection 0.5 mL, NDC 49281-0725-10, is a Sanofi Pasteur Inc. 45 ug / .5mL; 45 ug / .5mL; 45 ug / .5mL injection presentation packaged as 10 Syringe.
NDC search formats
- Canonical NDC 11: 49281-0725-10
- Digits-only NDC 11: 49281072510
- Possible 10-digit display format: 49281-725-10 (4928172510)
Helpful product links
- Search by brand name: Flublok Trivalent Northern Hemisphere
- NDC 11: 49281-0725-10
- Product family NDC: 49281-0725
- VA classification code: IM100
- VA classification code description: VACCINES
- CMOP ID: I0549
- VUID: 4032582
- UNSPSC code: 51201608
- Misc. Order Numbers: 1264140